Furthermore, α-IL-33 and α-ST2L treatments increased CD8+ T cell infiltration in the tumor site, which suggests that combination with α-PD-1 may enhance the anti-IL33 therapeutic efficacy in lung cancer. Here, CD8A is linked to neoplasm.